Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Tonix Pharmaceuticals from "hold" to "sell," and Weiss Ratings reaffirmed a "sell (e+)," though the consensus MarketBeat rating remains "Hold."
• Worse-than-expected quarterly results: Tonix reported EPS of ($3.98) vs. consensus ($3.16) and revenue of $5.39M, with very negative margins and analysts projecting steep fiscal-year losses.
• Clinical progress: The company announced the first participant dosed in a Phase 1 investigator‑initiated study of TNX‑1900 (intranasal oxytocin), an early-stage development that has increased media visibility but remains preliminary.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold".

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $12.88 on Friday. The company has a market capitalization of $172.59 million, a PE ratio of -0.90 and a beta of 1.88. The company's 50 day moving average price is $15.42 and its 200 day moving average price is $18.03. Tonix Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.16) by ($0.82). The company had revenue of $5.39 million during the quarter, compared to analysts' expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. On average, equities analysts forecast that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Seth Lederman acquired 15,000 shares of the company's stock in a transaction that occurred on Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, for a total transaction of $223,350.00. Following the completion of the acquisition, the chief executive officer owned 15,001 shares of the company's stock, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.03% of the company's stock.

Institutional Trading of Tonix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in shares of Tonix Pharmaceuticals during the 2nd quarter worth $25,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the 3rd quarter valued at $29,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Tonix Pharmaceuticals in the second quarter worth $62,000. Finally, State of Wyoming bought a new stake in Tonix Pharmaceuticals in the fourth quarter worth $27,000. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research's Estimate for TNXP FY2028 Earnings?

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.